BiotechTube

SHR-1314

Phase 1UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-severe Plaque Psoriasis

Conditions

Moderate-to-severe Plaque Psoriasis

Trial Timeline

Aug 2, 2018 → Jul 30, 2019

NCT ID
NCT03710681

About SHR-1314

SHR-1314 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Moderate-to-severe Plaque Psoriasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03710681. Target conditions include Moderate-to-severe Plaque Psoriasis.

What happened to similar drugs?

2 of 9 similar drugs in Moderate-to-severe Plaque Psoriasis were approved

Approved (2) Terminated (0) Active (7)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅dupilumabSanofiApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
6
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04527484Phase 1UNKNOWN
NCT04326881Phase 1UNKNOWN
NCT03710681Phase 1UNKNOWN
NCT03704428Phase 1Completed

Competing Products

13 competing products in Moderate-to-severe Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiApproved
43
dupilumabSanofiPre-clinical
26
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30